Elizabeth Ofili to Prospective Studies
This is a "connection" page, showing publications Elizabeth Ofili has written about Prospective Studies.
Connection Strength
0.634
-
Levites Strekalova YA, Kornetti DL, Pemu P, King Gordon T, Kumar D, Brown M, Spires S, Ofili EO. Strategic Team Science Promotes Collaboration and Practice-Based Research at the Research Centers in Minority Institutions. Int J Environ Res Public Health. 2023 03 09; 20(6).
Score: 0.170
-
Ofili EO, Schanberg LE, Hutchinson B, Sogade F, Fergus I, Duncan P, Hargrove J, Artis A, Onyekwere O, Batchelor W, Williams M, Oduwole A, Onwuanyi A, Ojutalayo F, Cross JA, Seto TB, Okafor H, Pemu P, Immergluck L, Foreman M, Mensah EA, Quarshie A, Mubasher M, Baker A, Ngare A, Dent A, Malouhi M, Tchounwou P, Lee J, Hayes T, Abdelrahim M, Sarpong D, Fernandez-Repollet E, Sodeke SO, Hernandez A, Thomas K, Dennos A, Smith D, Gbadebo D, Ajuluchikwu J, Kong BW, McCollough C, Weiler SR, Natter MD, Mandl KD, Murphy S. The Association of Black Cardiologists (ABC) Cardiovascular Implementation Study (CVIS): A Research Registry Integrating Social Determinants to Support Care for Underserved Patients. Int J Environ Res Public Health. 2019 05 10; 16(9).
Score: 0.131
-
Ofili E, Anand I, Williams RA, Akinboboye O, Xu L, Puckrein G. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure. Adv Ther. 2017 08; 34(8):1976-1988.
Score: 0.115
-
Ofili EO, Cable G, Neutel JM, Saunders E. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial. J Womens Health (Larchmt). 2008 Jul-Aug; 17(6):931-8.
Score: 0.062
-
Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL, Cushman WC, Sowers JR, Weber MA. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006 Apr; 98(4):618-26.
Score: 0.053
-
Norris KC, McCreath HE, Hueffer K, Aley SB, Chavira G, Christie CA, Crespi CM, Crespo C, D'Amour G, Eagan K, Echegoyen LE, Feig A, Foroozesh M, Guerrero LR, Johanson K, Kamangar F, Kingsford L, LaCourse W, Maccalla NM, M?rquez-Maga?a L, Mathur A, Maton K, Mehravaran S, Morales DX, Nakazono T, Ofili E, Okuyemi K, Ott L, Parangan-Smith A, Pfund C, Purnell D, Reynolds A, Rous PJ, Saetermoe C, Snyder K, Vishwanatha JK, Wagler A, Wallace SP, Seeman T. Baseline Characteristics of the 2015-2019 First Year Student Cohorts of the NIH Building Infrastructure Leading to Diversity (BUILD) Program. Ethn Dis. 2020; 30(4):681-692.
Score: 0.036
-
Brennan T, Spettell C, Villagra V, Ofili E, McMahill-Walraven C, Lowy EJ, Daniels P, Quarshie A, Mayberry R. Disease management to promote blood pressure control among African Americans. Popul Health Manag. 2010 Apr; 13(2):65-72.
Score: 0.017
-
Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Madder R, Weber MA. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36.
Score: 0.015
-
Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
Score: 0.013
-
Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, Weber MA. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
Score: 0.013
-
Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, Papademetriou V, Clark LT, Ofili EO, Randall OS, Oikarinen L, Viitasalo M, Toivonen L, Julius S, Dahl?f B, Devereux RB. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens. 2002 Aug; 15(8):663-71.
Score: 0.010